Enzomenib - Misplaced Pages

Pharmaceutical compound

Enzomenib
Clinical data

Other names	DSP-5336
Identifiers
IUPAC name 5-fluoro-2-octane-3-carbonyl]-2,7-diazaspirononan-2-yl]pyrimidin-5-yl]oxy-N,N-di(propan-2-yl)benzamide
CAS Number	2412555-70-3
PubChem CID	146430058
DrugBank	DB18514
ChemSpider	129534736
UNII	VW83Y2JLZ5
ChEMBL	ChEMBL5314915
Chemical and physical data
Formula	C₃₃H₄₃FN₆O₃
Molar mass	590.744 g·mol
3D model (JSmol)	Interactive image
SMILES CC(C)N(C(C)C)C(=O)C1=C(C=CC(=C1)F)OC2=CN=CN=C2N3CC4(C3)CCN(CC4)C(=O)56CC(N5)CC6=C
InChI InChI=InChI=1S/C33H43FN6O3/c1-20(2)40(21(3)4)31(41)26-15-23(34)6-9-27(26)43-28-16-35-19-36-30(28)39-17-33(18-39)10-12-38(13-11-33)32(42)29-25-8-7-24(37-29)14-22(25)5/h6,9,15-16,19-21,24-25,29,37H,5,7-8,10-14,17-18H2,1-4H3/t24-,25+,29-/m0/s1 Key:JQHJEDMMWUIYCE-FVVBACEJSA-N

Enzomenib is an investigational new drug that is being evaluated for the treatment of acute leukemia. It is a small molecule inhibitor that targets the interaction between menin and mixed-lineage leukemia (MLL) proteins. Enzomenib particularly in patients with KMT2A (MLL) rearrangements or NPM1 mutations.

The U.S. Food and Drug Administration (FDA) has granted both Fast Track and Orphan Drug designations to Enzomenib.

References

"Enzomenib - Sumitomo Pharma". AdisInsight. Springer Nature Switzerland AG.
Dempke WC, Desole M, Chiusolo P, Sica S, Schmidt-Hieber M (September 2023). "Targeting the undruggable: menin inhibitors ante portas". Journal of Cancer Research and Clinical Oncology. 149 (11): 9451–9459. doi:10.1007/s00432-023-04752-9. PMID 37103568.
"Sumitomo Pharma Presents New Clinical Data on DSP-5336 at the European Hematology Association 2024 Congress". Sumitomo Pharma Co., Ltd. 14 June 2024.
Flaherty C (15 July 2024). "FDA Grants Fast Track Designation to DSP-5336 in KMT2A/NMP1+ AML". OncLive.

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

Categories: